Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community.
ARVO LIVE: Luxa Biotechnology gives update on clinical trial of RPESC technology for dry AMD
April 24th 2023In a presentation during the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held at the Ernest N. Morial Convention Center in New Orleans, Luxa Biotechnology offered details of a clinical trial evaluating transplantation of cells derived from adult retinal pigmented epithelium stem cells to treat dry AMD.
ARVO LIVE: Lexitas modified National Eye Institute scale
April 23rd 2023Ophthalmology Times® talked with George Magrath, MD, and Andrew Pucker, OD, MS, PhD, FAAO at this year's ARVO meeting about Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.
IKA Keratoconus Symposium 2023: In-person white paper development, live patient Q&A
April 22nd 2023President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.
COPHy 2023: Debating the value of home monitoring as a management option for AMD
March 25th 2023The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal
COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye disease
March 25th 2023Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.